Breaking New Ground | ORR of 68% and mPFS of 11.2 Months! Sacituzumab Tirumotecan Plus Immunotherapy Explores a New First-Line Treatment Strategy for la/mUC

Breaking New Ground | ORR of 68% and mPFS of 11.2 Months! Sacituzumab Tirumotecan Plus Immunotherapy Explores a New First-Line Treatment Strategy for la/mUC

In recent years, the combination of antibody-drug conjugates (ADCs) and immunotherapy has transformed the treatment landscape for locally advanced or metastatic urothelial carcinoma (la/mUC). However, for patients who are ineligible for cisplatin, improving tumor response rates, prolonging disease control, and maintaining treatment tolerability and quality of life remain important clinical challenges. At the 2026 European Society for Medical Oncology (ESMO) Congress, a study of first-line treatment with a regimen combining China's homegrown TROP2 ADC sacituzumab tirumotecan and immunotherapy in la/mUC was presented in a Rapid Oral session [1]. Updated data showed a confirmed objective response rate (ORR) of 68%, a median duration of response (mDOR) of 19.4 months, and a median progression-free survival (mPFS) of 11.2 months. Effective and durable tumor responses were observed regardless of TROP2 or PD-L1 expression levels, providing important evidence to inform clinical treatment decisions. Oncology Frontier – UroStream invited Professor Dingwei Ye and Professor Xiaojie Bian of Fudan University Shanghai Cancer Center to discuss the study design, efficacy and safety findings, and the development of Chinese-originated ADCs in genitourinary oncology, with the aim of providing insights for clinical practice.
ESMO Preview | ORR of 68% and Median PFS of 11.2 Months: A New First-Line Strategy for la/mUC With Sacituzumab Tirumotecan Plus Immunotherapy

ESMO Preview | ORR of 68% and Median PFS of 11.2 Months: A New First-Line Strategy for la/mUC With Sacituzumab Tirumotecan Plus Immunotherapy

With advances in clinical research and updates to treatment guidelines, antibody–drug conjugate (ADC) combinations with immunotherapy have become a new standard of first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). The 2026 Congress of the European Society for Medical Oncology (ESMO) will be held in Madrid, Spain, from October 23 to 27, local time, featuring numerous cutting-edge studies in genitourinary oncology. Among them, data from a study of sacituzumab tirumotecan (Sac-TMT), a TROP2-targeted ADC developed in China, in first-line advanced urothelial carcinoma have been selected for a rapid oral presentation [1]. Updated results showed a confirmed objective response rate (ORR) of 68%, a median duration of response (DOR) of 19.4 months, and a median progression-free survival (PFS) of 11.2 months. Effective and durable tumor responses were observed regardless of patients' TROP2 and PD-L1 expression levels, suggesting a potential new treatment option for this population. The full text of the regular abstract has now been released. This article summarizes the latest developments and key findings for our readers.
Professor Yonghong Li: New Edition of the China Yearbook of Quality Control for Standardized Prostate Cancer Diagnosis and Treatment Released, With ADT Remaining the Cornerstone of Comprehensive Disease Management

Professor Yonghong Li: New Edition of the China Yearbook of Quality Control for Standardized Prostate Cancer Diagnosis and Treatment Released, With ADT Remaining the Cornerstone of Comprehensive Disease Management

Prostate cancer is one of the most common malignancies threatening men's health. In China, a high proportion of patients are diagnosed at the locally advanced or advanced stage, and overall outcomes continue to lag behind those in developed countries. Improving the overall effectiveness of prostate cancer treatment requires a systematic approach to standardizing and harmonizing diagnosis and treatment nationwide, with quality control for individual diseases serving as a key entry point. Since its establishment in 2021, the Prostate Cancer Quality Control Expert Committee of the National Cancer Center has systematically advanced the development of a quality control framework. The new edition of the China Yearbook of Quality Control for Standardized Prostate Cancer Diagnosis and Treatment (hereafter, the Quality Control Yearbook) was recently released. In an interview with Oncology Frontier, Professor Yonghong Li of Sun Yat-sen University Cancer Center shared her insights into prostate cancer epidemiology, the foundational role of androgen deprivation therapy (ADT), the standardized use of treatments and clinical indicators, and future directions for quality control.
ESMO 2026 | From Sustained First-Line Benefits to Earlier-Stage Exploration: Expanding the Evidence Base in Urothelial Carcinoma

ESMO 2026 | From Sustained First-Line Benefits to Earlier-Stage Exploration: Expanding the Evidence Base in Urothelial Carcinoma

The 2026 Congress of the European Society for Medical Oncology (ESMO) featured several important advances in urothelial carcinoma (UC). Nectin-4-targeted therapy continued to attract considerable attention, with 34 studies related to enfortumab vedotin presented, covering long-term follow-up of first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC), evidence of benefit across patient subgroups with different characteristics, and prospective investigations of perioperative treatment and bladder preservation in muscle-invasive bladder cancer (MIBC).
ESMO Voices from China | Professors Dawei Tian and Jianing Guo: HER2 Expression Heterogeneity in Bladder Carcinoma In Situ Reveals New Therapeutic Opportunities in Urothelial Carcinoma Beyond Invasive Disease

ESMO Voices from China | Professors Dawei Tian and Jianing Guo: HER2 Expression Heterogeneity in Bladder Carcinoma In Situ Reveals New Therapeutic Opportunities in Urothelial Carcinoma Beyond Invasive Disease

In recent years, HER2-targeted antibody–drug conjugates (ADCs), including disitamab vedotin, have demonstrated significant clinical value in the treatment of urothelial carcinoma (UC). However, HER2 expression in UC exhibits spatiotemporal heterogeneity. Bladder carcinoma in situ (CIS), in particular, is characterized by its occult presentation, high malignancy, and substantial risk of progression to invasive carcinoma. A standardized HER2 testing workflow for CIS is currently lacking, highlighting the need for further investigation. To address this challenge, a research team led by Professor Dawei Tian and Professor Jianing Guo of the Second Hospital of Tianjin Medical University conducted a clinical study whose findings were selected for presentation at the annual congress of the European Society for Medical Oncology (ESMO) [1], providing new evidence in this field. Oncology Frontier – UroStream invited both professors to discuss the clinical value of HER2, the characteristics of HER2 expression in CIS, the potential of disitamab vedotin in UC, and the implications of their findings for HER2 testing and clinical management.
A New Chapter of Innovation: Fudan University Shanghai Cancer Center Officially Establishes Its Urologic Oncology Center

A New Chapter of Innovation: Fudan University Shanghai Cancer Center Officially Establishes Its Urologic Oncology Center

In October 2026, as the autumn season ushers in a new chapter of progress and the spirit of excellence is passed on to the next generation, the Urologic Oncology Center of Fudan University Shanghai Cancer Center was officially established. In line with the hospital's strategic plan for the 15th Five-Year Plan period (2026–2030), which calls for the development of disease-specific centers, the initiative aims to build a nationally leading and internationally first-class center for urologic cancer diagnosis, treatment, and research. This milestone marks a new stage in the development of urologic oncology at the hospital, characterized by centralized leadership, coordinated operations across two campuses, and integrated development.
Professor Lei Wang: Applications of Holographic Imaging in Partial Nephrectomy 

Professor Lei Wang: Applications of Holographic Imaging in Partial Nephrectomy 

The urothelial carcinoma research team led by Professor Hailong Hu, Principal Investigator (PI) of the urothelial carcinoma subspecialty in the Department of Urology at the Second Hospital of Tianjin Medical University, has published the TRUCE-04 clinical study as an Original Investigation in JAMA Oncology, a leading international oncology journal with an impact factor of 23.9. The journal is part of the JAMA Network and is classified as a Chinese Academy of Sciences Q1 Top journal. The article is entitled “Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer.”
Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Treatment options for metastatic castration-resistant prostate cancer (mCRPC) are expanding rapidly. However, two major challenges remain in clinical decision-making: how to adjust treatment following oligoprogression and how to optimize the sequencing of precision therapies.
Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits

Professor Dingwei Ye and Professor Xiaojie Bian: Breaking Through Treatment Challenges in mCRPC with Sacituzumab Tirumotecan Plus Immunotherapy for Durable Survival Benefits

Patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression following novel endocrine therapy have very limited treatment options, presenting a major clinical challenge. In recent years, China has made substantial advances in innovative drug development, continuously reshaping treatment strategies. Novel TROP2 antibody-drug conjugates (ADCs), represented by sacituzumab tirumotecan, have demonstrated promising potential in prostate cancer. When combined with immunotherapy, the regimen achieved an overall objective response rate (ORR) of 47.4%, a disease control rate (DCR) of 89.5%, a duration of response (DoR) of 24.7 months, and a PSA50 response rate of 39.1% in the overall population. Median radiographic progression-free survival (rPFS) was 13.1 months, and median overall survival (OS) reached 22.8 months, potentially opening up a new treatment pathway for patients with mCRPC.
2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma

2026 CSCO | Professor Dingwei Ye and Professor Yao Zhu: Novel Breakthrough with a China-Developed TROP2 ADC—Sacituzumab Tirumotecan Demonstrates Significant Clinical Value in Advanced Urothelial Carcinoma

In recent years, treatment for urothelial carcinoma has advanced rapidly, with combination therapy involving targeted agents and immunotherapy significantly improving survival outcomes in patients with advanced disease. The CSCO Guidelines for the Diagnosis and Treatment of Urothelial Carcinoma have continued to incorporate emerging evidence, further enriching the standardized treatment framework. However, for most patients whose disease progresses following platinum-based chemotherapy and immunotherapy, subsequent treatment options remain extremely limited. Developing effective treatment strategies for patients receiving second-line and later-line therapy remains a major unmet need and a key clinical challenge in advanced urothelial carcinoma.